Search
At its Q3 2026 earnings briefing, BOTUO BIOTECH stated that the company remains committed to innovation-driven development, with POCT rapid diagnostics as its core business. The company continues to enhance its product portfolio, accelerate domestic and overseas registration and certification, advance the development of high-end microfluidic chip detection reagents for its microfluidic fluorescence detection platform, and strengthen the overall competitiveness of its POCT products. Meanwhile, the company is actively positioning itself at the frontiers of healthcare, exploring emerging directions such as brain-computer interfaces and AI healthcare by establishing an industrial investment platform to make equity investments or acquisitions and participate in industry funds, thereby opening up a long-term potential growth curve.
-
C114 Communication Network -
Communication Home
